Success Stories
The National Cancer Institute's (NCI) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are an important source of early-stage technology financing for small businesses. The NCI SBIR & STTR Programs foster research and development for anticancer agents, biomarkers, informatics, medical devices, nanotechnology, proteomics, pharmacodynamics, and many other biotechnologies and programs designed to prevent, diagnose, and treat cancer.
Click on the links below to learn more about how NCI SBIR & STTR Programs have helped small businesses and how successful SBIR & STTR applicants are using their funding awards to advance cancer research.
|
Altor BioScience Corporation
Altor BioScience Corporation, a Florida-based biopharmaceutical company, having already received millions in SBIR grant funding, was able to use $3 million in funding from the NCI Bridge Award to support clinical development of ALT-801, an immunotherapeutic for treatment of p53-positive cancers.
[ Read more ]
|
|
Advanced Cell Diagnostics
Advanced Cell Diagnostics (ACD), based in Silicon Valley, utilized the SBIR Phase I Grant funding to prove the feasibility of single RNA molecule detection in situ, increase the size of the company by over 80%, and complete the development of its RNAscope™ technology. As a result ACD is also furthering the progress of its cell-and tissue-based diagnostic tests for personalized medicine focusing on cancer.
[ Read more ]
|
|
AntiCancer
AntiCancer, the San Diego-based biotechnology company, was awarded Phase I and II SBIR grants and contracts that have led to the commercialization of three cancer research tools: MetaMouse®, AngioMouse®, and OncoBrite®.
[ Read more ]
|
|
Naviscan
Naviscan, a medical device company based in San Diego, used Phase I and II SBIR funding to bring improved breast cancer imaging technology through the stages of prototype building, clinical trials, and definitive post-marketing trials. The PEM Flex® PET Scanner now allows physicians to visualize breast tumors about the size of a grain of rice.
[ Read More ]
|
|
NovaRx
NovaRx, a biopharmaceutical company based in San Diego, has used SBIR funding since 2002 to successfully transition its vaccine platform technology from early research in immunogenicity to clinical trials that have shown promising results in non-small-cell lung cancer and other disease areas.
[ Read More ]
|
|
SBIR Phase II Bridge Awards
The SBIR Program awards Phase II Bridge Awards, a funding opportunity for promising cancer therapies and imaging technologies that more than triples the amount of funding available through the NCI SBIR Program and helps early stage biomedical companies bridge the funding gap known as the “Valley of Death” that exists between the end of a Phase II award and commercialization.
[ Read More ]
|
|
